14 results on '"Ananya"'
Search Results
2. ProtecTing Low-Risk Prostate Cancer.
- Author
-
Choudhury, Ananya
- Subjects
- *
PROSTATE cancer risk factors , *PROSTATE cancer prevention , *PROSTATE cancer treatment , *RADIOTHERAPY , *DIAGNOSIS , *PROSTATE cancer , *PROSTATE tumors , *RELATIVE medical risk - Published
- 2017
- Full Text
- View/download PDF
3. Similar Treatment Outcomes for Radical Cystectomy and Radical Radiotherapy in Invasive Bladder Cancer Treated at a United Kingdom Specialist Treatment Center
- Author
-
Kotwal, Sanjeev, Choudhury, Ananya, Johnston, Colin, Paul, Alan B., Whelan, Peter, and Kiltie, Anne E.
- Subjects
- *
BLADDER , *CANCER treatment , *RADIOTHERAPY , *URINARY organs - Abstract
Purpose: To conduct a retrospective analysis within a large university teaching hospital, comparing outcomes between patients receiving either radical surgery or radiotherapy as curative treatment for bladder cancer. Patients and Methods: Between March 1996 and December 2000, 169 patients were treated radically for muscle-invasive bladder cancer. Data were collected from patient notes. Statistical analyses were performed using Kaplan-Meier methods and Cox proportional hazards regression analysis to compare radiotherapy and surgical outcome data. Results: There was no difference in overall, cause-specific, and distant recurrence-free survival at 5 years between the two groups, despite the radiotherapy group being older (median age, 75.3 years vs. 68.2 years). There were 31 local bladder recurrences in the radiotherapy group (24 solitary), but there was no significant difference in distant recurrence-free survival. In a more recent (2002–2006) cohort, the median age of radiotherapy patients but not the cystectomy patients was higher than in the 1996–2000 cohort (78.4 years vs. 75.3 years for radiotherapy and 67.9 years vs. 68.2 years for surgery). Conclusions: Although the patients undergoing radical cystectomy were significantly younger than the radiotherapy patients, treatment modality did not influence survival. Bladder cancer patients are an increasingly elderly group. Radical radiotherapy is a viable treatment option for these patients, with the advantage of organ preservation. [Copyright &y& Elsevier]
- Published
- 2008
- Full Text
- View/download PDF
4. Toll-Like Receptor Agonists and Radiation Therapy Combinations: An Untapped Opportunity to Induce Anticancer Immunity and Improve Tumor control.
- Author
-
Walshaw, Richard C., Honeychurch, Jamie, Choudhury, Ananya, and Illidge, Timothy M.
- Subjects
- *
TOLL-like receptors , *RADIOTHERAPY , *IMMUNITY , *IMMUNOLOGIC memory , *T cells , *ANIMAL experimentation , *TOLL-like receptor agonists , *TUMORS , *COMBINED modality therapy - Abstract
The premise that therapies targeting immune checkpoints can enhance radiation therapy (RT)-induced antitumor immunity is being explored rigorously in the preclinical setting, and early clinical trials testing this hypothesis are beginning to report. Although such approaches might prove efficacious in certain settings, it is likely that many tumor types, particularly those that have a deeply immune-suppressed microenvironment with little or no T cell infiltration, will require alternative approaches. Thus, there is now considerable drive to develop novel immune modulatory therapies that target other areas of the cancer immunity cycle. Toll-like receptors (TLRs) are expressed on sentinel immune cells and play a key role in the host defense against invading pathogens. Innate sensing via TLR-mediated detection of pathogen-derived molecular patterns can lead to maturation of antigen-presenting cells and downstream activation of adaptive immunity. After demonstrating promising efficacy in preclinical studies, drugs that stimulate TLR have been approved for use clinically, albeit to a limited extent. There is a growing body of preclinical evidence that novel agonists targeting TLR3, TLR7/8, or TLR9 in combination with RT might lead to enhanced antitumor immunity. Mechanistic studies have revealed that TLR agonists enhance dendritic cell-mediated T cell priming after RT, in some cases leading to the generation of systemic antitumor immunity and immune memory. In this report, we describe results from preclinical studies that advocate the strategy of combining RT with TLR agonists, discuss reported mechanisms of action, and explore the exciting opportunities of how this approach may be successfully translated into clinical practice. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
5. External Beam Radiation Therapy (EBRT) and High-Dose-Rate (HDR) Brachytherapy for Intermediate and High-Risk Prostate Cancer: The Impact of EBRT Volume.
- Author
-
Tharmalingam, Hannah, Tsang, Yatman, Choudhury, Ananya, Alonzi, Roberto, Wylie, James, Ahmed, Imtiaz, Henry, Ann, Heath, Catherine, and Hoskin, Peter J.
- Subjects
- *
DATABASES , *RESEARCH , *MICROMETASTASIS , *ANTIANDROGENS , *RESEARCH methodology , *METASTASIS , *EVALUATION research , *MEDICAL cooperation , *COMPARATIVE studies , *RESEARCH funding , *RADIOTHERAPY , *RADIOISOTOPE brachytherapy , *PROSTATE-specific antigen , *BLOOD coagulation factors , *PROSTATE tumors , *TUMOR grading , *LONGITUDINAL method - Abstract
Purpose: Whole pelvis radiation therapy (WPRT) may improve clinical outcomes over prostate-only radiation therapy (PORT) in high-risk prostate cancer patients by sterilization of micrometastatic nodal disease, provided there is optimal control of the primary site.Methods and Materials: A prospective multicenter cohort study of eligible patients (stage ≥T2c, Gleason score ≥7 or presenting prostate-specific antigen ≥10) treated between 2009 and 2013 were enrolled in a United Kingdom national protocol delivering combined external beam radiation therapy and high-dose-rate brachytherapy. Centers elected to deliver WPRT, 46 Gy in 23 fractions or PORT 37.5 Gy in 15 fractions with 15 Gy single dose high-dose-rate brachytherapy. The primary endpoint was biochemical progression-free survival (bPFS). Secondary endpoints were overall survival, genitourinary, and gastrointestinal toxicity. This was not a randomized comparison and was subject to bias; the findings are therefore hypothesis generating, but not conclusive.Results: Eight hundred and twelve patients were entered; 401 received WPRT and 411 received PORT. With a median follow-up of 4.7 years, 5-year bPFS rates for WPRT versus PORT arms were 89% versus 81% (P = .007) for all patients and 84% versus 77% (P = .001) for high-risk patients. Differences in bPFS remained significant after accounting for Gleason score, presenting prostate-specific antigen, T stage, and androgen deprivation therapy duration as covariates. There was no difference in overall survival. The overall post treatment toxicities across both cohorts were low with no greater than 1.5% of ≥grade 3 toxicities at any follow-up time point. WPRT increased both prevalence and cumulative incidence of acute genitourinary toxicity (P = .004) and acute gastrointestinal toxicity (P = .003). No difference in late radiation toxicity was observed.Conclusions: A significant improvement in 5-year bPFS was seen in intermediate and high-risk prostate cancer treated with WPRT compared with PORT in a combined external beam radiation therapy and brachytherapy schedule with no increase in late radiation toxicity. [ABSTRACT FROM AUTHOR]- Published
- 2020
- Full Text
- View/download PDF
6. SBRT for Localized Prostate Cancer: Is it Ready for Take-Off?
- Author
-
Mitin, Timur, Henry, Ann, Choudhury, Ananya, Chen, Ronald C., Pinkawa, Michael, and Spratt, Daniel E.
- Subjects
- *
PROSTATE cancer , *LOW dose rate brachytherapy , *HIGH dose rate brachytherapy , *RADIOTHERAPY , *CASTRATION-resistant prostate cancer - Published
- 2019
- Full Text
- View/download PDF
7. Nonrandomized Comparison of Efficacy and Side Effects of Bicalutamide Compared With Luteinizing Hormone-Releasing Hormone (LHRH) Analogs in Combination With Radiation Therapy in the CHHiP Trial.
- Author
-
Tree, Alison, Griffin, Clare, Syndikus, Isabel, Birtle, Alison, Choudhury, Ananya, Graham, John, Ferguson, Catherine, Khoo, Vincent, Malik, Zafar, O'Sullivan, Joe, Panades, Miguel, Parker, Chris, Rimmer, Yvonne, Scrase, Christopher, Staffurth, John, Dearnaley, David, Hall, Emma, and CHHiP investigators
- Subjects
- *
RADIOTHERAPY , *LUTEINIZING hormone , *HORMONE therapy , *PROGNOSIS , *PROSTATE cancer , *SULFUR compounds , *ANTIANDROGENS , *CLINICAL trials , *MEDICAL care , *ORGANIC compounds , *CARDIOVASCULAR system , *RESEARCH funding , *QUESTIONNAIRES , *DRUG side effects , *PROSTATE tumors , *AMIDES - Abstract
Purpose: CHHiP is a randomized trial evaluating moderately hypofractionated radiation therapy for treatment of localized prostate cancer. Of all participants, 97% of them had concurrent short-course hormone therapy (HT), either luteinizing hormone-releasing hormone analog (LHRHa) or 150 mg of bicalutamide daily. This exploratory analysis compares efficacy and side effects in a nonrandomized comparison.Methods and Materials: In our study, 2700 patients received LHRHa and 403 received bicalutamide. The primary endpoint was biochemical/clinical failure. Groups were compared with Cox regression adjusted for various prognostic factors and stratified by radiation therapy dose. A key secondary endpoint was erectile dysfunction (ED) assessed by clinicians (using scores from Late Effects on Normal Tissues: Subjective/Objective/Management [LENT-SOM] subjective erectile function for vaginal penetration) and patients (single items within the University of California-Los Angeles Prostate Cancer Index [UCLA PCI] and Expanded Prostate Cancer Index Composite [EPIC]-50 questionnaires) at 2 years and compared between HT regimens by χ2 trend test.Results: Bicalutamide patients were significantly younger (median 67 vs 69 years LHRHa). Median follow-up was 9.3 years. There was no difference in biochemical or clinical failure with an adjusted hazard ratio or 0.97 (95% confidence interval, 0.77-1.23; P = .8). At 2 years, grade ≥2 LENT-SOM ED was reported in significantly more LHRHa patients (313 out of 590; 53%) versus bicalutamide (17 out of 68; 25%) (P < .0001). There were no differences in ED seen with UCLA-PCI and EPIC-50 questionnaires.Conclusions: In this nonrandomized comparison, there was no evidence of a difference in efficacy according to type of HT received. Bicalutamide preserved clinician assessed (LENT-SOM) erectile function at 2 years but patient-reported outcomes were similar between groups. [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
8. Long-Term Outcomes of Radical Radiation Therapy with Hypoxia Modification with Biomarker Discovery for Stratification: 10-Year Update of the BCON (Bladder Carbogen Nicotinamide) Phase 3 Randomized Trial (ISRCTN45938399).
- Author
-
Song, Yee Pei, Mistry, Hitesh, Irlam, Joely, Valentine, Helen, Yang, Lingjian, Lane, Brian, West, Catharine, Choudhury, Ananya, Hoskin, Peter J., and Hoskin, Peter
- Subjects
- *
BLADDER cancer , *NICOTINAMIDE , *RADIOTHERAPY , *OVERALL survival , *HYPOXEMIA , *CLINICAL prediction rules , *CANCER invasiveness , *OXYGEN therapy , *RESEARCH , *CONFIDENCE intervals , *TIME , *RESEARCH methodology , *REGRESSION analysis , *PROGNOSIS , *MEDICAL cooperation , *EVALUATION research , *VITAMIN B complex , *TREATMENT effectiveness , *COMPARATIVE studies , *RANDOMIZED controlled trials , *CARBON dioxide , *RADIATION-sensitizing agents , *RESEARCH funding , *NECROSIS , *LONGITUDINAL method ,BLADDER tumors - Abstract
Purpose: Many muscle-invasive bladder cancers are hypoxic, which limits the efficacy of radiation therapy. Hypoxia modification using carbogen and nicotinamide has been tested in a phase 3 trial, Bladder Carbogen Nicotinamide. We present mature follow-up data with biomarker predictions of outcomes.Methods and Materials: Bladder Carbogen Nicotinamide is a prospective, phase 3, multicenter, randomized, 2-arm, nonblinded clinical trial. Participants were randomized to receive radical radiation therapy (RT; control arm) alone or with the addition of carbogen (98% O2; 2% CO2) and nicotinamide (CON). Patients with muscle-invasive or high-grade non-muscle invasive bladder cancer were included. Tumor tissue was collected at entry and was analyzed for tumor necrosis, hypoxia (24-gene signature), and basal and luminal tumor molecular subtypes. Overall survival (OS) and disease-free survival and relationships with biomarker status outcomes are analyzed using multivariable Cox regression and log-rank analysis.Results: We analyzed 333 patients with a median follow-up of 10.3 years. The 10-year OS rates were 30% (95% confidence interval [CI], 0.23-0.39) in RT + CON patients and 24% (95% CI, 0.18-0.33) in the RT-alone patients (hazard ratio [HR], 0.80; 95% CI, 0.61-1.04; P = .08). The greatest benefit from CON was seen in patients with tumor necrosis (n = 79; 5-year OS, 53% vs. 33% in patients without tumor necrosis; HR, 0.59; 95% CI, 0.36-0.99; P = .04). Cases with a high hypoxia gene score (n = 75) had a 5-year OS rate of 51%, compared to 34% for a low score (HR, 0.64; 95% CI, 0.38-1.08; P = .09); those with the basal molecular subtype (n = 70) had a 5-year OS rate of 58%, compared to 38% for those with the luminal subtype (HR, 0.58; 95% CI, 0.32-1.06; P = .08).Conclusions: Although the improvement in long-term OS in the whole population is not statistically significant, patients selected by necrosis and high hypoxia gene score benefitted from hypoxia modification. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
9. Ten-Year Outcomes of Moderately Hypofractionated Salvage Postprostatectomy Radiation Therapy and External Validation of a Contemporary Multivariable Nomogram for Biochemical Failure.
- Author
-
Chin, Stephen, Fatimilehin, Abiola, Walshaw, Richard, Argarwal, Arjun, Mistry, Hitesh, Elliott, Tony, Logue, John, Wylie, James, and Choudhury, Ananya
- Subjects
- *
VALIDATION therapy , *RADIOTHERAPY , *NOMOGRAPHY (Mathematics) , *WASTE salvage , *SEMINAL vesicles , *LIMB salvage , *GLEASON grading system - Abstract
Purpose: Although high-level evidence supports moderately hypofractionated radiation therapy for definitive prostate treatment, there is less evidence for its use in the postprostatectomy setting. We externally validated a contemporary nomogram predicting biochemical failure (BF) after salvage radiation therapy (SRT) and report long-term disease control outcomes for hypofractionated SRT to the prostate bed.Methods and Materials: A retrospective review was performed for 112 patients treated with hypofractionated SRT (52.5 Gy in 20 fractions using 3-dimensional conformal radiation therapy) for pT2-4R0-1N0/XM0 prostate adenocarcinoma, with postoperative prostate-specific antigen (PSA) greater than 0.1 ng/mL or rising. Freedom from BF (FFBF), distant metastasis, cancer-specific mortality, and overall survival were analyzed from commencement of radiation therapy. Cox regression was performed on FFBF to account for covariates. BF was defined as a PSA ≥0.4 ng/mL and rising after SRT. Early SRT was defined as SRT commencing at a pre-SRT PSA of ≤0.2 ng/mL.Results: Median follow-up was 10.0 years (interquartile range, 9.3-10.7 years), median pre-SRT PSA was 0.4 ng/mL, and androgen deprivation therapy was used in 14% of patients. The 5/10-year FFBF, distant metastasis, cancer-specific mortality, and overall survival were 68%/51%, 7%/16%, 5%/11%, and 90%/75%, respectively. FFBF for early SRT compared with late SRT was 81% versus 66% at 5 years and 68% versus 49% at 10 years. On multivariable analysis, pre-SRT PSA, International Society of Urologic Pathology grade group, seminal vesicle invasion, and androgen deprivation therapy use were associated with FFBF. The nomogram c-index was 0.67, and it overestimated FFBF by 10% and 15% at 5 and 10 years, respectively, with confidence intervals overlapping the line of unity.Conclusions: Hypofractionated SRT provides long-term disease control outcomes comparable to conventionally fractionated radiation therapy. Early SRT provides improved disease control, with two-thirds of patients with pre-SRT PSA of ≤0.2 ng/mL free of BF at 10 years. We performed the first external validation of the Tendulkar salvage nomogram, which showed a robust model performance. [ABSTRACT FROM AUTHOR]- Published
- 2020
- Full Text
- View/download PDF
10. Palliative Radiation Therapy in Bladder Cancer-Importance of Patient Selection: A Retrospective Multicenter Study.
- Author
-
Ali, Amin, Song, Yee Pei, Mehta, Shaveta, Mistry, Hitesh, Conroy, Ruth, Coyle, Catherine, Logue, John, Tran, Anna, Wylie, James, Janjua, Tanzeel, Joseph, Lisa, Joseph, Joji, and Choudhury, Ananya
- Subjects
- *
PATIENT selection , *RADIOTHERAPY , *CANCER treatment , *BLADDER cancer , *TREATMENT effectiveness , *RETROSPECTIVE studies , *COMPARATIVE studies , *LONGITUDINAL method , *RESEARCH methodology , *MEDICAL cooperation , *PALLIATIVE treatment , *RADIATION doses , *RESEARCH , *TIME , *EVALUATION research , *FUTILE medical care ,BLADDER tumors - Abstract
Purpose: To investigate the effectiveness of palliative pelvic radiation therapy (PRT) in patients with bladder cancer and identify factors associated with treatment outcome.Methods and Materials: Patients with bladder cancer receiving PRT were identified retrospectively from 2 cancer centers between 2014 and 2017. Patients were stratified by age, stage, performance status, comorbidities, previous chemotherapy, previous radiation therapy, and radiation therapy protocol. Patients were followed up at 6 weeks after radiation therapy (RT). Median overall survival (mOS) from the last fraction of RT was calculated. Death within 30 days of RT or noncompletion of treatment were considered as futile treatment.Results: Two hundred forty-one patients were identified as receiving PRT. A variety of RT protocols were used: 8 Gy in 1 fraction (11%), 21 Gy in 3 fractions (15%), 20 Gy in 5 fractions (18%), 36 Gy in 6 fractions (36%), and 27.5 to 30 Gy in 8 to 10 fractions (18%). Thirty-eight percent of patients were of poor performance status (Eastern Cooperative Oncology Group performance status ≥3), and 46.5% had significant comorbidities (Adult Comorbidity Evaluation-27 ≥2). The mOS from the last fraction of RT was 153 days (0-1289 days). The 30-day mortality after radiation therapy was 18% (n = 44), and the rate of incomplete planned radiation therapy treatment was 14% (n = 33). First follow-up information was available in 62% (n = 150) of patients. Median time to this follow-up was 49 days (14-238 days). At first follow-up at about 6 weeks after the last fraction of radiation therapy, symptoms were reported in 150 of 200 (75%) living patients; 80 of 150 (53%) patients reported improvement in symptoms after treatment. There were significant differences in mOS with stage, performance status, and comorbidities.Conclusions: One in 4 patients either did not complete the planned RT course or died within 30 days of treatment. These patients were unlikely to have received maximal benefit from treatment but may have experienced side effects, making treatment futile. Patients with good performance status and earlier stage disease survived longer. Patient selection and comprehensive assessment are crucial in selecting appropriate patients for treatment. [ABSTRACT FROM AUTHOR]- Published
- 2019
- Full Text
- View/download PDF
11. MRE11 as a Predictive Biomarker of Outcome After Radiation Therapy in Bladder Cancer.
- Author
-
Walker, Alexandra K., Karaszi, Katalin, Valentine, Helen, Strauss, Victoria Y., Choudhury, Ananya, McGill, Shaun, Wen, Kaisheng, Brown, Michael D., Ramani, Vijay, Bhattarai, Selina, Teo, Mark T.W., Yang, Lingjian, Myers, Kevin A., Deshmukh, Nayneeta, Denley, Helen, Browning, Lisa, Love, Sharon B., Iyer, Gopa, Clarke, Noel W., and Hall, Emma
- Subjects
- *
BLADDER cancer , *RADIOTHERAPY , *CANCER treatment , *DECISION making , *STANDARD operating procedure - Abstract
Organ-confined muscle-invasive bladder cancer is treated with cystectomy or bladder preservation techniques, including radiation therapy. There are currently no biomarkers to inform management decisions and aid patient choice. Previously we showed high levels of MRE11 protein, assessed by immunohistochemistry (IHC), predicted outcome after radiation therapy, but not cystectomy. Therefore, we sought to develop the MRE11 IHC assay for clinical use and define its relationship to clinical outcome in samples from 2 major clinical trials. Samples from the BCON and BC2001 randomized controlled trials and a cystectomy cohort were stained using automated IHC methods and scored for MRE11 in 3 centers in the United Kingdom. Despite step-wise creation of scoring cards and standard operating procedures for staining and interpretation, there was poor intercenter scoring agreement (kappa, 0.32; 95% confidence interval, 0.17-0.47). No significant associations between MRE11 scores and cause-specific survival were identified in BCON (n = 132) and BC2001 (n = 221) samples. Reoptimized staining improved agreement between scores from BCON tissue microarrays (n = 116), but MRE11 expression was not prognostic for cause-specific survival. Manual IHC scoring of MRE11 was not validated as a reproducible biomarker of radiation-based bladder preservation success. There is a need for automated quantitative methods or a reassessment of how DNA-damage response relates to clinical outcomes. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
12. The Efficacy and Safety of Conventional and Hypofractionated High-Dose Radiation Therapy for Prostate Cancer in an Elderly Population: A Subgroup Analysis of the CHHiP Trial.
- Author
-
Wilson, James M., Dearnaley, David P., Syndikus, Isabel, Khoo, Vincent, Birtle, Alison, Bloomfield, David, Choudhury, Ananya, Graham, John, Ferguson, Catherine, Malik, Zafar, Money-Kyrle, Julian, O'Sullivan, Joe M., Panades, Miguel, Parker, Chris, Rimmer, Yvonne, Scrase, Christopher, Staffurth, John, Stockdale, Andrew, Cruickshank, Clare, and Griffin, Clare
- Subjects
- *
RADIOTHERAPY , *PROSTATE cancer patients , *PROSTATE cancer treatment , *ANDROGENS , *BLADDER cancer , *ANTIANDROGENS , *AGE distribution , *BLADDER , *COMPARATIVE studies , *INTESTINES , *LONGITUDINAL method , *RESEARCH methodology , *MEDICAL cooperation , *PROSTATE tumors , *RADIATION injuries , *RESEARCH , *RESEARCH funding , *STATISTICAL sampling , *EVALUATION research , *RANDOMIZED controlled trials , *DISEASE incidence , *THERAPEUTICS - Abstract
Purpose: Outcome data on radiation therapy for prostate cancer in an elderly population are sparse. The CHHiP (Conventional or Hypofractionated High Dose Intensity Modulated Radiotherapy in Prostate Cancer) trial provides a large, prospectively collected, contemporary dataset in which to explore outcomes by age.Methods and Materials: CHHiP participants received 3 to 6 months of androgen deprivation therapy and were randomly assigned (1:1:1) to receive 74 Gy in 37 fractions (conventional fractionation), 60 Gy in 20 fractions, or 57 Gy in 19 fractions. Toxicity was assessed using clinician-reported outcome (CRO) and patient-reported outcome questionnaires. Participants were categorized as aged < 75 years or ≥ 75 years. Outcomes were compared by age group.Results: Of 3216 patients, 491 (15%) were aged ≥ 75 years. There was no difference in biochemical or clinical failure rates between the groups aged < 75 years and ≥ 75 years for any of the fractionation schedules. In the group aged ≥ 75 years, biochemical or clinical failure-free rates favored hypofractionation, and at 5 years, they were 84.7% for 74 Gy, 91% for 60 Gy, and 87.7% for 57 Gy. The incidence of CRO (grade 3) acute bowel toxicity was 2% in both age groups. The incidence of grade 3 acute bladder toxicity was 8% in patients aged < 75 years and 7% in those aged ≥ 75 years. The 5-year cumulative incidence of CRO grade ≥ 2 late bowel side effects was similar in both age groups. However, in the group aged ≥ 75 years, there was a suggestion of a higher cumulative incidence of bowel bother (small or greater) with 60 Gy compared with 74 Gy and 57 Gy. Patient-reported bladder bother was slightly higher in the group aged ≥ 75 years than the group aged < 75 years, and there was a suggestion of a lower cumulative incidence of bladder bother with 57 Gy compared with 74 Gy and 60 Gy in patients aged ≥ 75 years, which was not evident in those aged < 75 years.Conclusions: Hypofractionated radiation therapy appears to be well tolerated and effective in men aged ≥ 75 years. The 57-Gy schedule has potential advantages in that it may moderate long-term side effects without compromising treatment efficacy in this group. [ABSTRACT FROM AUTHOR]- Published
- 2018
- Full Text
- View/download PDF
13. Magnetic Resonance Imaging-Guided Adaptive Radiation Therapy: A "Game Changer" for Prostate Treatment?
- Author
-
Pathmanathan, Angela U., van As, Nicholas J., Kerkmeijer, Linda G.W., Christodouleas, John, Lawton, Colleen A.F., Vesprini, Danny, van der Heide, Uulke A., Frank, Steven J., Nill, Simeon, Oelfke, Uwe, van Herk, Marcel, Li, X. Allen, Mittauer, Kathryn, Ritter, Mark, Choudhury, Ananya, and Tree, Alison C.
- Subjects
- *
PROSTATE cancer treatment , *RADIOTHERAPY , *MAGNETIC resonance imaging , *CANCER patients , *RADIOBIOLOGY - Abstract
Radiation therapy to the prostate involves increasingly sophisticated delivery techniques and changing fractionation schedules. With a low estimated α/β ratio, a larger dose per fraction would be beneficial, with moderate fractionation schedules rapidly becoming a standard of care. The integration of a magnetic resonance imaging (MRI) scanner and linear accelerator allows for accurate soft tissue tracking with the capacity to replan for the anatomy of the day. Extreme hypofractionation schedules become a possibility using the potentially automated steps of autosegmentation, MRI-only workflow, and real-time adaptive planning. The present report reviews the steps involved in hypofractionated adaptive MRI-guided prostate radiation therapy and addresses the challenges for implementation. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
14. "But We Are Already Geriatric Oncologists"-Why Older Patients Need a Special Approach (A View from a United Kingdom Cancer Center).
- Author
-
Cree, Anthea, Hawthorn, Tania, Pemberton, Laura, Cowan, Richard, and Choudhury, Ananya
- Subjects
- *
GERIATRIC nursing , *CANCER treatment , *RADIOTHERAPY , *CANCER diagnosis , *COGNITIVE ability - Published
- 2017
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.